CPT code 19082 represents a stereotactically guided percutaneous breast biopsy performed for each additional separately reportable lesion beyond the first, with optional concurrent placement of a localization device. This procedure code is important nationally because it captures additional lesion sampling during breast diagnostic workups, which affects encounter coding, resource use, and multisite lesion management. Payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will gain a concise clinical and billing context for 19082, including the procedure’s role in breast imaging workflows, typical sites of service, and how reporting an additional-lesion biopsy differs from primary-lesion coding. The publication summarizes common modifier usage and payer considerations where available, highlights implications for documentation and billing practice, and clarifies the scope of services bundled or separately reportable. The content is aimed at coding professionals, revenue cycle managers, and clinical leaders who need to align documentation with billing for stereotactic breast biopsies. Data not available in the input will be explicitly noted in the relevant sections.